LEADER 05576nam 2200661 450 001 9910464946503321 005 20200520144314.0 010 $a1-4619-4820-7 010 $a1-61705-151-9 035 $a(CKB)3710000000021207 035 $a(EBL)1481033 035 $a(OCoLC)861559303 035 $a(SSID)ssj0001039921 035 $a(PQKBManifestationID)11702387 035 $a(PQKBTitleCode)TC0001039921 035 $a(PQKBWorkID)10991453 035 $a(PQKB)10983947 035 $a(MiAaPQ)EBC1481033 035 $a(Au-PeEL)EBL1481033 035 $a(CaPaEBR)ebr10775825 035 $a(CaONFJC)MIL539961 035 $a(EXLCZ)993710000000021207 100 $a20130611d2014 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aGynecologic cancers $ea multidisciplinary approach to diagnosis and management /$fedited by Kunle Odunsi, Tanja Pejovic 210 1$aNew York :$cDemos Medical Publishing,$d2014. 215 $a1 online resource $cillustrations (some color) 225 0$aCurrent multidisciplinary oncology 300 $aDescription based upon print version of record. 311 $a1-936287-89-7 320 $aIncludes bibliographical references and index. 327 $aCover; Title; Copyright; Contents; Series Foreword; Preface; Contributors; Part I: Cervical Cancer and Precancerous Lesions; Chapter 1: The Biology of Human Papillomavirus and the Etiology of Female Genital Tract Cancers; Viral Structure and Genomic Organization; Viral Life Cycle; Tissue-Specific Pathogenesis; Biological Markers of Progression; Clinical Models For HPV-related Disease; References; Chapter 2: Cervical Cancer Prevention: HPV Vaccines; HPV Vaccine Development; References; Chapter 3: Cervical Cancer Prevention: Screening and Diagnostic Accuracy 327 $aCervical Cancer Screening and the Papanicolaou (PAP) SmearHigh-Risk Human Papillomavirus (HPV) Testing; The Role of Colposcopic Biopsies; Molecular Markers of HPV-Mediated Neoplastic Transformation; Improved Diagnostic Accuracy using Neoplastic Markers; Future Screening; References; Chapter 4: Management of Cervical Dysplasia and Precancerous Lesions; Colposcopic Terminology; Human Papillomavirus (HPV) Positive, Cytology Negative; HPV Negative, Ascus Cytology; HPV Positive, Ascus Cytology or LSIL or More Severe Cytology Regardless of HPV Status; CIN1 with ASCUS, ASC-H, or LSIL Cytology 327 $aCIN1 with HSIL or AGC CytologyCIN2,3; CIN2,3 in Adolescent and Young Women; AIS; Pregnancy; HIV-Positive Women; References; Chapter 5: Management of Recurrent Cervical Cancer; Background; Surveillance; Local Recurrences After Primary Surgical Management; Local Recurrences After Radiotherapy; Distant Recurrences or Nonoperable Local Recurrences; Conclusion; References; Chapter 6: Multimodality Treatment of Rare Cervical Cancer; Rare AC; GCC; Conclusion; References; Chapter 7: Principles of Radiation Therapy for Cervical Cancer; Introduction; EBRT; Brachytherapy 327 $aIndications and Treatment OutcomesReferences; Part II: Multidisciplinary Approach to Cancer of the Uterine Corpus; Chapter 8: Surgical-Pathologic Features of Uterine Cancers; Endometrial Carcinoma; Endometrial Hyperplasia; Practical Considerations on Endometrial Biopsy; References; Chapter 9: Multidisciplinary Approach to Treatment of Endometrioid Uterine Carcinoma; Surgery for Early Endometrial Cancer; Surgery for Advanced Endometrial Cancer (stage III-IV); References; Chapter 10: Principles of Radiation Therapy for Uterine Cancers; Adjuvant Radiation; Advanced Disease; Recurrent Disease 327 $aMedically Inoperable PatientsFuture Studies; Summary; References; Chapter 11: Multidisciplinary Management of Serous Carcinoma of the Endometrium; Epidemiology, Molecular Pathogenesis, and Biologic Behavior; Diagnosis, Management, and Prognosis; Emerging Therapies; Summary; References; Chapter 12: Multidisciplinary Approach to Diagnosis and Treatment of Uterine Sarcomas; Uterine Leiomyosarcoma; Endometrial Stromal Sarcomas; Other Sarcomas; Conclusions; References; Part III: Epithelial Ovarian Cancer; Chapter 13: Molecular Pathogenesis of Ovarian Cancer; Introduction 327 $aEtiology of Sporadic Epithelial Ovarian Carcinoma 330 $aOver the course of the last decade, the treatment of gynecologic cancer has evolved quite rapidly. New scientific and clinical advances have modified the standard of care and led to improved patient outcomes. At the same time, the treatment of gynecologic cancer has become increasingly complex, requiring the comprehensive review and assessment of multiple issues including genetics, radiology, surgery, molecular diagnostics, chemotherapy, and more. As a result, the harmony and open communication between these specialties facilitated by a multidisciplinary team approach are crucial in providing 410 0$aCurrent multidisciplinary oncology. 606 $aGenerative organs, Female$xDiseases$xDiagnosis 606 $aGenerative organs, Female$xDiseases$xTreatment 608 $aElectronic books. 615 0$aGenerative organs, Female$xDiseases$xDiagnosis. 615 0$aGenerative organs, Female$xDiseases$xTreatment. 676 $a616.99/46 701 $aOdunsi$b Kunle$01027297 701 $aPejovic$b Tanja$01027298 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910464946503321 996 $aGynecologic cancers$92442653 997 $aUNINA